BioCentury
ARTICLE | Clinical News

Hepatitis C: Phase IIa

December 24, 2001 8:00 AM UTC

INNX said that 28-week interim results from a placebo-controlled Phase IIa trial in Belgium in 35 patients with HCV showed that the vaccine is well tolerated and that antibody and T cell responses to ...